Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” second-quarter 2025 investor letter ...

Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a Phase 3 ...

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Novo Nordisk ( NVO 1.34%) and Regeneron Pharmaceuticals ( REGN -0.27%), two leading drugmakers, have underperformed for most ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huynh raised the price target on Regeneron Pharmaceuticals, Inc.

Short-term stock returns are largely driven by the perception of near-term earnings per share. Read more here.

Regeneron Pharmaceuticals is on the cusp of unveiling its Q2 2025 earnings this Friday, with expectations pinned at $8.53 per share and a revenue forecast of $3.30 billion. Analysts are eyeing a ...

Mediolanum International Funds Ltd has supercharged its investment in Regeneron Pharmaceuticals, increasing its stake by a ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

We expect Amgen AMGN to beat expectations when it reports second-quarter 2025 results on Aug. 5 after market close. In the ...

Fujifilm delivered strong FY2025 results, driven by progress on VISION2030 and a diversified business mix. Read why FUJIY stock is a Buy.